Literature DB >> 11560788

End-stage Liver Disease in Children.

Robert H. Squires1.   

Abstract

The treatment of children with end-stage liver disease involves the coordinated management of nutritional deficiencies, ascites, pruritus, encephalopathy, and portal hypertension. The implementation of management strategies depends upon a parent or guardian to administer the plan in the context of a child at different stages of developmental, physiologic, emotional, and physical maturity. Fat-soluble vitamins (A, D, E, and K) and micronutrient levels should be monitored routinely and supplemented if deficient. In some patients, supplemental nutrition to provide additional energy and protein is needed to ensure optimal growth and development. Ascites often respond to spironolactone and sodium restriction, but may require the addition of a loop diuretic or even abdominal paracentesis. Pruritus significantly impairs the quality of life of patients and is typically treated with ursodeoxycholic acid, rifampin, or an antihistamine. Partial biliary diversion, or liver transplant in some instances, is necessary for patients with self-mutilating pruritus that results from intrahepatic cholestasis. Hepatic encephalopathy is poorly defined in infants and small children. Elevated serum ammonia serves as a surrogate marker for encephalopathy, which is treated with dietary protein restriction and lactulose. The usefulness of medical prophylaxis for esophageal varices has been noted in adults, though such studies have not been performed in children. If variceal bleeding becomes problematic, treatment with endoscopic variceal banding or sclerotherapy is indicated. A surgical shunt to reduce portal pressure is needed in some cases. Orthotopic liver transplant ultimately may be necessary to overcome the unrelenting consequences of end-stage liver disease.

Entities:  

Year:  2001        PMID: 11560788     DOI: 10.1007/s11938-001-0006-6

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  39 in total

1.  Minnesota rickets. Need for a policy change to support vitamin D supplementation.

Authors:  E A Eugster; K S Sane; D M Brown
Journal:  Minn Med       Date:  1996-08

2.  Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis.

Authors:  L Laine; D Cook
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

3.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Rifampin relieves pruritus in children with cholestatic liver disease.

Authors:  H A Cynamon; J M Andres; R P Iafrate
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

Review 5.  Hepatic encephalopathy and ascites.

Authors:  R Jalan; P C Hayes
Journal:  Lancet       Date:  1997-11-01       Impact factor: 79.321

6.  d-Alpha-tocopheryl polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood.

Authors:  E A Argao; J E Heubi; B W Hollis; R C Tsang
Journal:  Pediatr Res       Date:  1992-02       Impact factor: 3.756

7.  Endoscopic ligation of esophageal varices in children.

Authors:  V L Fox; D L Carr-Locke; P J Connors; A M Leichtner
Journal:  J Pediatr Gastroenterol Nutr       Date:  1995-02       Impact factor: 2.839

8.  Bleeding as the first symptom of extrahepatic biliary atresia.

Authors:  R H Houwen; J Bouquet; C M Bijleveld
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

9.  Portosystemic shunting for paediatric portal hypertension.

Authors:  A Shun; D P Delaney; H C Martin; G M Henry; M Stephen
Journal:  J Pediatr Surg       Date:  1997-03       Impact factor: 2.545

10.  Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis.

Authors:  R J Sokol; N Butler-Simon; C Conner; J E Heubi; F R Sinatra; F J Suchy; M B Heyman; J Perrault; R J Rothbaum; J Levy
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

View more
  1 in total

1.  Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.